Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
EXECUTIVE INTERVIEW - Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics August 31, 2022
Bill Hartzel, Senior Vice President and Head of CDMO Business, discusses the company’s plans for current and future CDMO operations and client partnership opportunities.
2022 Analytical Testing eBook – Service Providers Offer Innovation August 23, 2022
Learn more about the technologies from Alcami, Associates of Cape Cod, Stevanato Group, and West in this exclusive 2022 Drug Development & Delivery Analytical Testing e-book.
Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo August 1, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary...Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates August 1, 2022
Vaxxinity, Inc. recently presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the….
MediWound Announces Positive Initial Data From Phase 1/2 Study for the Treatment of Basal Cell Carcinoma July 11, 2022
MediWound Ltd. recently announced positive initial data from 11 patients in its ongoing open-label Phase 1/2 study of MW005 for...Protega Pharmaceuticals LLC Announces Commercialization of Oxycodone Hydrochloride Tablets CII in the US July 6, 2022
Protega Pharmaceuticals LLC recently announced the commercial launch of RoxyBond (oxycodone) immediate-release (IR) tablets in the US. RoxyBond was approved...US Government to Support Expansion of Croda Lipid Systems Capability June 29, 2022
Croda International Plc recently announced it has entered into a cooperative agreement with the US government in which the government will provide up to $75 million to expand the….
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis June 28, 2022
Soligenix, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for a Phase 2a clinical...SCYNEXIS Announces Initiation of New Phase 3b Study to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis June 23, 2022
SCYNEXIS, Inc. recently announced the initiation and first patient enrolled in a new Phase 3b, open-label, multicenter study (VANQUISH) to evaluate...Exavir Therapeutics Announces Preclinical Data for Ultra-Long-Acting Dolutegravir Prodrug XVIR-120 June 9, 2022
Exavir Therapeutics recently announced the publication of preclinical data for XVIR-120, an investigational agent being developed as a long-acting injectable antiviral for HIV….
Catalent & MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19 June 7, 2022
Catalent and MigVax recently announced they have signed a development agreement to leverage Catalent’s proprietary Zydis Bio orally disintegrating tablet...Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next-Generation Core Inhibitor June 6, 2022
Assembly Biosciences, Inc. recently announced the initiation of a Phase 1b trial of its investigational next-generation, highly potent core inhibitor...Evonik Invests $220 Million to Build New Lipid Production Facility for mRNA-based Therapies in the US June 2, 2022
Evonik is building a new, highly flexible, global-scale production facility for pharmaceutical lipids in the US. The new plant at...Enteris BioPharma to Exhibit at CPhI North America 2022 May 9, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly owned...Hovione & JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program May 9, 2022
Hovione, the leader in spray drying and particle engineering, recently announced an exclusive license agreement for a preclinical ophthalmology program, JX08, with….
SPECIAL FEATURE - PFS & Parenteral Drug Delivery: Self-Injection is Very Much the “New Normal” May 2, 2022
Contributor Cindy H. Dubin showcases how leading CDMOs and drug delivery developers are responding to current market trends to create ergonomic technologies that are patient friendly, easy to use, reduce needle anxiety, and feature improved packaging materials.
EXECUTIVE INTERVIEW - PCI Pharma Services: Broadening Our Biologics Footprint, Together May 2, 2022
Shawn Cain, SVP Development & Manufacturing at PCI Pharma Services, discusses the recent acquisition, the opportunities this presents to Biopharma companies, and the current trends in the sterile fill-finish industry.
Caladrius Biosciences & Cend Therapeutics Announce Definitive Merger Agreement April 27, 2022
Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. recently announced the companies have entered into a definitive merger agreement under which Cend will merge with a wholly owned subsidiary of….
Blacktrace Launches Particle Works – The New Dedicated Particle Engineering Brand April 22, 2022
Particle Works’ game-changing particle engineering platforms are set to revolutionize the way customers discover, develop and scale-up particle production for a wide range of….
Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate April 21, 2022
Blue Water Vaccines Inc. recently issued the below statement regarding its Form 8-K filed with the Securities and Exchange Commission...Company Profiles
Lyophilization Technology, Inc.
Lyophilization Technology, Inc. 30 Indian Drive Ivyland, PA 18974-1431 T: (215) 396-8373 F: (215) 396-8375 E: inquiry@lyo-t.com W: www.lyotechnology.com WHO...DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products
Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.
